Article
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
PloS one - 1 Jan 2022
Milbury Coren A, Creeden James, Yip Wai-Ki, Smith David L, Pattani Varun, Maxwell Kristi, Sawchyn Bethany, Gjoerup Ole, Meng Wei, Skoletsky Joel, Concepcion Alvin D, Tang Yanhua, Bai Xiaobo, Dewal Ninad, Ma Pei, Bailey Shannon T, Thornton James, Pavlick Dean C, Frampton Garrett M, Lieber Daniel, White Jared, Burns Christine, Vietz Christine
Abstract excerpt
FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) technology to examine 324 cancer genes in solid tumors. F1CDx...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.